Universal reference book for medicines
Name of the drug: PREGABALIN-RICHTER (PREGABALIN-RICHTER)

Active substance: pregabalin

Type: Anticonvulsant drug

Manufacturer: GEDEON RICHTER (Hungary) produced by GEDEON RICHTER-RUS (Russia)

Composition, form of production and packaging
Capsules
hard gelatinous, size 4 Coni-Snap, with yellow lid and body;
the contents of the capsules are crystalline powder of white or almost white color.
1 caps.

pregabalin 25 mg

Excipients: lactose monohydrate 35 mg, corn pregelatinized corn starch 26 mg, corn starch 13 mg, talc 1 mg.

The composition of the cap of the gelatin capsule: titanium dioxide - 0.8742%, dye quinoline yellow - 0.3497%, dye sunset yellow - 0.0116%, gelatin - up to 100%.

The composition of the gelatin capsule body: titanium dioxide - 0.8742%, dye quinoline yellow - 0.3497%, dye sunset yellow - 0.0116%, gelatin - up to 100%.

14 pcs.
- blisters (1) - packs of cardboard.
14 pcs.
- blisters (4) - packs of cardboard.
Capsules hard gelatinous, size 3 Coni-Snap, with a light brown lid and yellow body;
the contents of the capsules are crystalline powder of white or almost white color.
1 caps.

pregabalin 50 mg

Excipients: lactose monohydrate - 70 mg, corn pregelatinized corn starch - 52 mg, corn starch - 26 mg, talc - 2 mg.

Composition of the capsule of the gelatin capsule: 1% titanium dioxide, 1.2% iron oxide yellow oxide, 0.32% iron oxide red color, 0.1% iron oxide black oxide, 100% gelatin.

The composition of the gelatin capsule body: titanium dioxide - 0.8742%, dye quinoline yellow - 0.3497%, dye sunset yellow - 0.0116%, gelatin - up to 100%.

14 pcs.
- blisters (1) - packs of cardboard.
14 pcs.
- blisters (4) - packs of cardboard.
Capsules hard gelatinous, size 4 Coni-Snap, with a light brown lid and body;
the contents of the capsules are crystalline powder of white or almost white color.
1 caps.

pregabalin 75 mg

Excipients: lactose monohydrate - 8.25 mg, corn starch - 15.75 mg, talc - 1 mg.

Composition of the capsule of the gelatin capsule: 1% titanium dioxide, 1.2% iron oxide yellow oxide, 0.32% iron oxide red color, 0.1% iron oxide black oxide, 100% gelatin.

The composition of the gelatin capsule body: 1% titanium dioxide, 1.2% iron oxide yellow oxide, 0.32% iron oxide red color, 0.1% iron oxide black oxide, 100% gelatin.

14 pcs.
- blisters (1) - packs of cardboard.
14 pcs.
- blisters (4) - packs of cardboard.
Capsules hard gelatinous, size 3 Coni-Snap, with brown lid and yellow body;
the contents of the capsules are crystalline powder of white or almost white color.
1 caps.

pregabalin 100 mg

Excipients: lactose monohydrate - 11 mg, corn starch - 21 mg, talc - 1.33 mg.

The composition of the cap of the gelatin capsule: titanium dioxide 0.2%, iron dye oxide yellow 0.3%, iron dye oxide red 0.7%, ferric iron oxide black 0.4%, gelatin 100%.

The composition of the gelatin capsule body: titanium dioxide - 0.8742%, dye quinoline yellow - 0.3497%, dye sunset yellow - 0.0116%, gelatin - up to 100%.

14 pcs.
- blisters (1) - packs of cardboard.
14 pcs.
- blisters (4) - packs of cardboard.
Capsules hard gelatinous, size 2 Coni-Snap, with brown lid and body;
the contents of the capsules are crystalline powder of white or almost white color.
1 caps.

pregabalin 150 mg

Excipients: lactose monohydrate - 16.5 mg, corn starch - 31.5 mg, talc - 2 mg.

The composition of the cap of the gelatin capsule: titanium dioxide 0.2%, iron dye oxide yellow 0.3%, iron dye oxide red 0.7%, ferric iron oxide black 0.4%, gelatin 100%.

The composition of the body of the gelatin capsule: titanium dioxide 0.2%, iron dye oxide yellow 0.3%, iron dye red oxide 0.7%, iron dye oxide black 0.4%, gelatin 100%.

14 pcs.
- blisters (1) - packs of cardboard.
14 pcs.
- blisters (4) - packs of cardboard.
Capsules hard gelatinous, size 1 Coni-Snap, with a dark brown lid and yellow body;
the contents of the capsules are crystalline powder of white or almost white color.
1 caps.

pregabalin 200 mg

Excipients: lactose monohydrate - 22 mg, corn starch - 42 mg, talc - 2.66 mg.

The composition of the capsule of the gelatin capsule: iron oxide red oxide - 1.4286%, ferric oxide black oxide - 2.2857%, gelatin - up to 100%.

The composition of the gelatin capsule body: titanium dioxide - 0.8742%, dye quinoline yellow - 0.3497%, dye sunset yellow - 0.0116%, gelatin - up to 100%.

14 pcs.
- blisters (1) - packs of cardboard.
14 pcs.
- blisters (4) - packs of cardboard.
Capsules hard gelatinous, size No. 0 Coni-Snap, with a dark brown lid and body;
the contents of the capsules are crystalline powder of white or almost white color.
1 caps.

pregabalin 300 mg

Excipients: lactose monohydrate - 33 mg, corn starch - 63 mg, talc - 4 mg.

The composition of the capsule of the gelatin capsule: iron oxide red oxide - 1.4286%, ferric oxide black oxide - 2.2857%, gelatin - up to 100%.

The composition of the gelatin capsule body: iron oxide red oxide - 1.4286%, ferric oxide black oxide - 2.2857%, gelatin - up to 100%.

14 pcs.
- blisters (1) - packs of cardboard.
14 pcs.
- blisters (4) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2017.

PHARMACHOLOGIC EFFECT

Anticonvulsant drug.
Pregabalin is an analogue of gamma-aminobutyric acid ((S) -3- (aminomethyl) -5-methylhexanoic acid).
It was established that pregabalin binds to the additional subunit (? 2- delta-protein) of the potential-dependent calcium channels in the CNS, irreversibly replacing [3H] -gabapentin.
It is suggested that such binding can promote the manifestation of analgesic and anticonvulsant effects of pregabalin.
Neuropathic pain

Pregabalin is effective in patients with diabetic neuropathy and postherpetic neuralgia.

It has been established that when taking pregabalin by courses up to 13 weeks 2 times / day and up to 8 weeks 3 times / day, the risk of side effects and the effectiveness of the drug at 2 or 3 times / day are the same.

When taking a course of up to 13 weeks, the pain decreased during the first week, and the effect persisted throughout the course of therapy.

In 35% of patients on the background of the use of pregabalin and in 18% of patients receiving placebo, the pain index was reduced by 50%.
Among patients who received pregabalin and did not show drowsiness, a 50% reduction in the pain index was noted in 33% of cases; among patients who received placebo, this figure was 18%. Drowsiness was noted in 48% of patients receiving pregabalin, and in 16% of patients receiving placebo.
Fibromyalgia

The expressed decrease in pain symptoms in fibromyalgia was noted in patients receiving pregabalin in a dose of 300-600 mg / day.
The efficacy of doses of 450 mg and 600 mg / day was comparable, but a dose of 600 mg / day was usually worse tolerated. In addition, against the background of the use of pregabalin, there was an improvement in the functional activity of patients, as well as a decrease in the severity of sleep disturbances. The use of pregabalin in a dose of 600 mg / day led to a more pronounced improvement in sleep, compared with a dose of 300-450 mg / day.
Epilepsy

At reception of a preparation within 12 weeks on 2 or 3 times / s the risk of development of undesirable reactions and efficiency of a preparation at these modes of dosing are identical.
Reduction in the frequency of seizures is noted already during the first week of taking the drug.
Generalized anxiety disorder

Reduction of symptoms of generalized anxiety disorder is noted in the first week of treatment.
After 8 weeks of treatment, a 50% reduction in Hamilton anxiety symptoms (NAM-A) was observed in 52% of patients treated with pregabalin and 38% of patients receiving placebo.
PHARMACOKINETICS

In healthy volunteers, patients with epilepsy, who received antiepileptic therapy, and in patients who received pregabalin for relief of chronic pain syndromes, similar indicators of the pharmacokinetics of pregabalin in equilibrium were observed.

Suction

Pregabalin is rapidly absorbed after ingestion on an empty stomach.
C max in blood plasma is achieved after 1 h both with a single and repeated application.Bioavailability of pregabalinum at intake makes? 90% and does not depend on the dose. With repeated use, C ss is reached after 24-48 hours. The meal reduces Cmax byabout 25-30%, and the time to reach Cmax increases to about 2.5 h.
However, eating does not have a clinically significant effect on the overall absorption of pregabalin.

Distribution

The apparent V d of pregabalin after oral administration is approximately 0.56 l / kg.
Pregabalin does not bind to blood plasma proteins.
Metabolism

Pregabalinum is practically not exposed to a metabolism.
After taking labeled pregabalin, approximately 98% of the radioactive label was detected in the urine unchanged. The proportion of the N-methylated pregabalin derivative, which is the main metabolite found in the urine, was 0.9% of the dose. There were no signs of racemization of the S-enantiomer of pregabalin into the R-enantiomer.
Excretion

Pregabalin is excreted mainly by the kidneys in unchanged form.
The mean T 1/2 is 6.3 h. The clearance of pregabalin from the plasma and the kidney clearance are directly proportional to the CK.
Linearity / nonlinearity

The pharmacokinetics of pregabalin when applied in the range of recommended daily doses is linear, interindividual variability is low (less than 20%).

The pharmacokinetics of pregabalin with repeated application can be predicted on the basis of single dose data.
Therefore, there is no need for regular monitoring of pregabalin concentrations in blood plasma.
Pharmacokinetics in specific patient groups

Clearance of pregabalin is directly proportional to QC.
Given that pregabalin is mainly excreted by the kidneys, in patients with impaired renal function it isrecommended to reduce the dose of pregabalin. In addition, pregabalin is effectively removed from the blood plasma during hemodialysis (after a 4-hour hemodialysis session, pregabalin concentration in the blood plasma is reduced by approximately 50%), after hemodialysis, an additional dose of the drug should be prescribed.
Special pharmacokinetic studies in patients with impaired liver function were not performed.
Since pregabalin is practically not metabolized and excreted mainly by the kidneys in an unchanged form, the violation of liver function should not significantly affect the pregabalin concentration in the blood plasma.
Clearance of pregabalin with age tends to decrease, which reflects the age-related decrease in QC.
Elderly patients (over 65 years) with impaired renal function may need to reduce the dose of the drug.
The sex of the patient does not have a clinically significant effect on the concentration of pregabalin in the blood plasma.

INDICATIONS

Neuropathic pain:

- treatment of neuropathic pain in adult patients.

Epilepsy:

- as an additional therapy in adult patients with partial seizures, accompanied or not accompanied by secondary generalization.

Generalized anxiety disorder:

- treatment of generalized anxiety disorder in adult patients.

Fibromyalgia:

- treatment of fibromyalgia in adult patients.

DOSING MODE

The drug is used inside, regardless of food intake, at a dose of 150 to 600 mg / day in 2 or 3 divided doses.

Neuropathic pain

The initial dose of pregabalin is 150 mg / day.
Depending on the effect achieved and tolerance in 3-7 days, the dose can be increased to 300 mg / day, and, if necessary, after 7 days - up to a maximum dose of 600 mg / day.
Epilepsy

The initial dose of pregabalin is 150 mg / day.
Taking into account the achieved effect and tolerability after 1 week, the dose can be increased to 300 mg / day, and in a week - up to a maximum dose of 600 mg / day.
Fibromyalgia

The initial dose of pregabalin is 75 mg 2 times / day (150 mg / day).
Depending on the effect achieved and the tolerance in 3-7 days, the dose can be increased to 300 mg / day. In the absence of a positive effect, the dose is increased to 450 mg / day, and if necessary, after 7 days - up to a maximum dose of 600 mg / day.
Generalized anxiety disorder

The initial dose of pregabalin is 150 mg / day.
Depending on the effect achieved and the tolerability after 7 days, the dose can be increased to 300 mg / day. In the absence of a positive effect, the dose is increased to 450 mg / day, and if necessary, after 7 days - up to a maximum dose of 600 mg / day.
Abolition of the drug

If treatment with pregabalin should be stopped, it is recommended to do this gradually for at least 1 week.

For patients with impaired renal function, the dose is individually adjusted for KK (Table 1), which is calculated by the following formula:

KK (ml / min) = (140 - age in years)?
body weight (kg) / 72? serum creatinine (mg / dL)
For women, the result should be multiplied by 0.85.

Patients who are undergoing hemodialysis receive a daily dose of pregabalin given the kidney function.
Immediately after each 4-hour hemodialysis session, an additional dose is prescribed (see Table 1).
Table 1. Selection of a dose of pregabalin with account of kidney function

Creatinine clearance (ml / min) Daily pregabalin dose Multiplicity of administration per day

Initial dose (mg / day) Maximum dose (mg / day)

> 60 150 600 2-3

? 30- <60 75 300 2-3

? 15- <30 25-50 150 1-2

<15 25 75 1

Additional dose after a hemodialysis session (mg)

25 100 one-off

In patients with impaired liver function , dose adjustment is not required.

Safety and efficacy of pregabalin in children under 12 years of age and adolescents (12-17 years of age) has not been established.
The use of the drug in children is not recommended.
Older patients (over 65 years of age) may need to reduce the dose of pregabalin due to a decrease in kidney function.

In case of missing a dose of pregabalin, the next dose should be taken as soon as possible.
Do not take a double dose of the drug. Resume the usual medication the next day.
SIDE EFFECT

According to the experience of clinical use of the drug in more than 12 000 patients, the most common adverse events were dizziness and drowsiness.
Typically, adverse events were mild or moderate. The frequency of cancellation of pregabalin and placebo due to adverse events was 14% and 7%, respectively. The main undesirable phenomena that required cessation of treatment were dizziness (4%) and drowsiness (3%), depending on their individual tolerability. Other side effects leading to withdrawal of the drug were ataxia, confusion, asthenia, impaired attention, blurred vision, impaired coordination, peripheral edema.
Undesirable phenomena are classified according to system-organ classes and frequency: very often (> 1/10), often (> 1/100, <1/10), infrequently (> 1/1000, <1/100), rarely (<1 / 1000), the frequency is unknown (the frequency can not be estimated from the available data).
The listed undesirable phenomena could be associated with the underlying disease and / or concomitant therapy.
Infections and infestations: infrequently - nasopharyngitis.

From the hemopoietic system: rarely - neutropenia.

From the side of metabolism: often - increased appetite;
infrequently - anorexia, hypoglycemia.
From the side of the psyche: often - euphoria, confusion, decreased libido, insomnia, irritability, disorientation;
infrequently - depersonalization, anorgasmia, anxiety, depression, agitation, mood lability, depressed mood, difficulty in word selection, hallucinations, unusual dreams, increased libido, panic attacks, apathy, increased insomnia; rarely - disinhibition, high spirits.
From the nervous system: very often - dizziness, drowsiness;
often - ataxia, impaired attention, impaired coordination, memory impairment, tremor, dysarthria, paresthesia, imbalance, amnesia, sedation, lethargy; infrequently - cognitive disorders, hypoesthesia, nystagmus, speech impairment, myoclonic spasms, hyporeflexia, dyskinesia, psychomotor agitation, postural dizziness, hyperesthesia, loss of taste, burning sensation on the mucous membranes and skin, intentional tremor, stupor, fainting; rarely - hypokinesia, parosmia, dysgraphy; frequency unknown - headache, loss of consciousness, cognitive impairment, convulsions.
From the side of the organ of vision: often - blurred vision, diplopia;
infrequent - narrowing of the visual fields, reduced visual acuity, eye pain, asthenopia, dry eyes, puffiness of the eyes, increased lacrimation; rarely - flashes of sparks before the eyes, eye irritation, mydriasis, oscilloscopy (subjective sensation of fluctuations in the subjects under consideration), impaired perception of visual depth, loss of peripheral vision, strabismus, increased brightness of visual perception; frequency unknown - keratitis, loss of vision.
From the side of the organ of hearing and balance: often - vertigo;
infrequently - a hyperacusis.
From the cardiovascular system: infrequently - tachycardia, AV-blockade of the I degree, "hot flashes", a decrease in blood pressure, cold extremities, increased blood pressure, skin hyperemia;
rarely - sinus tachycardia, sinus arrhythmia, sinus bradycardia; frequency unknown - chronic heart failure, prolongation of QT interval.
From the respiratory system: infrequently - shortness of breath, cough, dryness of the nasal mucosa;
rarely - nasal congestion, nosebleed, rhinitis, snoring, a feeling of "restraint" in the throat; frequency unknown - pulmonary edema.
On the part of the digestive system: often - dry mouth, constipation, vomiting, flatulence, bloating;
infrequently - increased salivation, gastroesophageal reflux, hypoesthesia of the oral mucosa; rarely - ascites, dysphagia, pancreatitis; frequency unknown - rare cases of edema of the tongue, nausea, diarrhea.
From the skin and subcutaneous fat: rarely - sweating, papular rash;
rarely - cold sweat, hives; frequency unknown - rare cases of face swelling, itching, Stevens-Johnson syndrome.
From the musculoskeletal system: infrequently - muscle twitching, swelling of the joints, muscle spasms, myalgia, arthralgia, back pain, pain in the limbs, stiffness of the muscles;
rarely - spasm of the neck muscles, neck pain, rhabdomyolysis.
From the side of the kidneys and urinary tract: infrequently - dysuria, urinary incontinence;
rarely - oliguria, renal insufficiency; frequency unknown - urinary retention.
On the part of the immune system: the frequency is unknown - angioedema, allergic reactions, hypersensitivity.

On the part of the reproductive system: often - erectile dysfunction;
infrequently - delay of ejaculation, sexual dysfunction; rarely - amenorrhea, pain in the mammary glands, discharge from the mammary glands, dysmenorrhea, enlargement of mammary glands in the volume; frequency unknown - gynecomastia.
Other: often - fatigue, swelling (including peripheral), a sense of "intoxication," a violation of gait;
infrequently - asthenia, falls, thirst, a feeling of restraint in the chest, generalized edema, chills, pain, pathological sensations; rarely - hyperthermia.
On the part of laboratory indicators: often - an increase in body weight;
infrequently - increased ALT, AST, KFK, a decrease in the number of platelets; rarely - increasing the concentration of glucose and creatinine, reducing blood potassium, reducing body weight, reducing the number of leukocytes in the blood.
CONTRAINDICATIONS

- rare hereditary diseases, incl.
intolerance to galactose, lactase deficiency or glucose-galactose malabsorption;
- child and adolescence to 17 years inclusive (due to lack of data);
- Hypersensitivity to the active substance or any other component of the drug.

With caution should be used drug in renal and heart failure, as well as in patients with drug dependency history (such patients require close medical supervision during treatment with the drug).
PREGNANCY AND LACTATION

Data on the use of pregabalin in pregnant women is not enough. Studies using animal signs of reproductive toxicity of the drug have been reported. Therefore, pregabalin can be used during pregnancy only if the expected benefit to the mother clearly outweighs the potential risk to the fetus.
In applying the drug women of childbearing age should use adequate contraception.
Information about the penetration of pregabalin in the breast milk of women do not have, but noted that in lactating rats, it is excreted in the milk. In this regard, pregabalin breast-feeding is not recommended during treatment.
APPLICATION FOR FUNCTIONS OF THE LIVER

Pregabalin clearance is directly proportional to creatinine clearance. Given that pregabalin is mainly excreted by the kidneys in patients with impaired renal function it is advisable to reduce the dose of pregabalin (see. Dosing regimen). Furthermore, pregabalin is effectively removed from the blood plasma during hemodialysis (after 4-hour hemodialysis session pregabalin concentration in blood plasma decreases by about 50%), after dialysis need to assign an additional dose of drug.
APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

In patients with impaired liver function no dose adjustment is required.
APPLICATION FOR CHILDREN

The safety and effectiveness of pregabalin in children under the age of 12 years and adolescents (12-17 years) has not been established.
The use of the drug in children is not recommended.
APPLICATION IN ELDERLY PATIENTS

Elderly patients (over 65 years) may require dose reduction of pregabalin due to declining renal function.
SPECIAL INSTRUCTIONS

Some patients with diabetes mellitus in the case of body weight gain during treatment with pregabalin may require correction doses hypoglycemic agents. In the case of angioedema symptoms (such as swelling of the face, perioral edema or swelling of the upper airway tissue) should stop reception of pregabalin.
Antiepileptic drugs, including pregabalin, may increase the risk of suicidal thoughts or behavior. Therefore, patients receiving these drugs should be closely monitored for the emergence or worsening of depression, the emergence of suicidal thoughts or behavior.
Pregabalin treatment was accompanied by dizziness and drowsiness, which increase the risk of accidental injury (fall) in elderly patients. During post-marketing use of pregabalin were also reported cases of loss of consciousness, confusion and impaired cognitive function. Therefore, as long as patients do not appreciate the possible effects of the drug, they should be careful.
Information about the possibility of cancellation of other anticonvulsant drugs after reaching the control of seizures during treatment with pregabalin, and the feasibility of monotherapy pregabalin, is not enough.
There are reports of the development of seizures, including.
status epilepticus and small seizures during treatment with pregabalin or immediately after the end of therapy.
When in response to the use of pregabalin undesirable reactions such as blurred vision, or other violations of the organ of vision, removal of the drug can promote disappearance of the symptoms.
Also, cases of renal failure with pregabalin therapy were reported; in some cases after discontinuation of renal function is restored.
As a result of cancellation of pregabalin after prolonged or short-term therapy, the following undesirable phenomena were observed: insomnia, headache, nausea, diarrhea, flu-like syndrome, depression, sweating, dizziness, convulsions and anxiety.
Information about the frequency and severity of manifestations of the "withdrawal" of pregabalin depending on the dose and duration of therapy are not available.
During post-marketing use of pregabalin reported on the development of chronic heart failure in some patients receiving pregabalin. Mostly, these reactions were observed in elderly patients with impaired cardiac function who received pregabalin over neuropathy. Therefore, pregabalin should be used with caution in these patients.
After the abolition of pregabalin, the disappearance of manifestations of such reactions is possible.
In the treatment of central neuropathic pain due to spinal cord lesion, there was an increase in adverse reactions in the central nervous system, such as drowsiness. This may be due to the additive effect on the background of the simultaneous application of pregabalin and other drugs (e.g., antispastic). This fact should be considered when appointments pregabalin for the treatment of central neuropathic pain.
Reported cases of dependence in the application of pregabalin.
Patients with drug dependence in a history need careful medical observation for symptoms of dependence on pregabalin.
Cases of encephalopathy, particularly in patients with underlying medical conditions that could contribute to its development.
Impact on the ability to drive vehicles and operate machinery with an increased risk of injury
Pregabalin may cause dizziness and somnolence and therefore affect the ability to drive vehicles and to operate machinery. Patients should not drive and use machines or perform other potentially hazardous activities until it is clear whether the drug affects the ability of these actions.
OVERDOSE

Symptoms. During post-marketing use of pregabalin most common adverse events in overdose were affective disorders, drowsiness, confusion, depression, agitation and anxiety. When a drug overdose (15 g) was unexpected adverse events were registered.
Treatment: gastric lavage, supportive therapy, and if necessary - hemodialysis.
DRUG INTERACTION

Since pregabalin is mainly excreted by the kidneys in unchanged form, undergoes minimal metabolism in man (as metabolites kidneys displayed less than 2% of the dose) did not inhibit metabolism of other in vitro drug and does not bind to blood plasma proteins, it is unlikely to enter into a pharmacokinetic interaction.
No indication of clinically significant pharmacokinetic interactions with pregabalin, phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone and ethanol. It was found that oral hypoglycemic agents, diuretics, insulin, phenobarbital, tiagabine and topiramate does not have a clinically significant effect on pregabalin clearance.
The use of oral contraceptives containing norethisterone and / or ethinyl, simultaneously with pregabalin does not affect the equilibrium pharmacokinetics of drugs.
In patients treated with pregabalin and drugs that suppress the central nervous system, there have been cases of respiratory failure and coma.
Reported cases negative effect of pregabalin on gastrointestinal function (including the development of ileus, paralytic ileus, constipation), while the use of drugs causing constipation (such as non-narcotic analgesics).
Reapply pregabalin inside with oxycodone, lorazepam or ethanol had no clinically significant effect on respiration. It is assumed that pregabalin enhances cognitive impairment and motor function caused by oxycodone.
Pregabalin can enhance the effects of ethanol and lorazepam.
TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored out of reach of children at a temperature of no higher than 25 В° C.
Shelf life - 2 years.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!